Tisento Therapeutics
Peter Hecht is a seasoned executive in the biotechnology and pharmaceutical sectors, currently serving as Chief Executive Officer at Tisento Therapeutics since July 2023. Previously, Peter has held significant leadership roles, including Co-Founder and CEO at Cyclerion from 2019 to July 2023 and Co-Founder and CEO at Ironwood Pharmaceuticals from 1998 to 2019. Peter also contributes to various organizations as a Board Member at Mythic Therapeutics, Inc. and Kallyope, and as an Advisory Board Member at Ariadne Labs. Peter's academic background includes a Doctor of Philosophy in Molecular Biology from the University of California, Berkeley, a Master of Science in Biology from Stanford University, and a Bachelor of Science in Mathematics from Stanford University.
This person is not in any teams
This person is not in any offices
Tisento Therapeutics
Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.